Obesity Market Intelligence Newsletter

The anti-obesity treatment landscape has completely transformed over the past few years, and as demand continues to drive further innovation, it can be difficult for decision makers to cut through the noise and understand which developments are most critical to the industry.

To help you stay up to date with the latest clinical, commercial, and regulatory changes, Airfinity is launching a free weekly newsletter compiling all the information and analysis you need to inform your strategies. Whether you have a candidate in clinical trials, are looking to understand uptake and the role payers should be playing, or even want to know how the wider anti-obesity treatment market is impacting other industries, sign up today to ensure you stay ahead of the curve.

SELECT trial readout: secondary endpoint implications and Airfinity forecast accuracy:

SELECT examined the long-term cardiovascular outcomes of patients with pre-existing cardiovascular disease given 2.4 mg semaglutide (Wegovy) over a mean follow-up of 3 years and 4 months. The trial met its primary endpoint, reducing major adverse cardiovascular events (MACE; a composite comprised of, non-fatal myocardial infarction, non-fatal stroke and cardiovascular death) by 20%. The number needed to treat in order to prevent one MACE was 67 – very close to Airfinity’s prediction of 63 in August.

Airfinity’s projections indicate that with moderate coverage, deaths among eligible patients in the US could be reduced by 11% and new onset type 2 diabetes by 43%. With high coverage, deaths could be reduced by 15%, and type 2 diabetes cases by almost two thirds in the same patient population. To discuss access Airfinity's scenario-based forecasting models and the implications these have for the wider cardiometabolic landscape, get in touch here.

Sign up today!

Fill out this short form to be instantly added to our newsletter.

Sign up today!

Fill out this short form to be instantly added to our newsletter.

What our users say?


“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”

Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister

hm government

“Airfinity has been instrumental in our country's COVID response.”

Head of UK Government
Vaccine Task Force


In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”

Iskra Reic, Executive Vice-President


“Probably the most expansive, accurate and helpful of the multiple data sets on an international scale”

Sir John Bell ,
University of Oxford